Meredith E Giuliani
Overview
Explore the profile of Meredith E Giuliani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
383
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giuliani M, Salunkhe R, Warner A, Palma D
Int J Radiat Oncol Biol Phys
. 2025 Feb;
121(4):1089.
PMID: 39988419
No abstract available.
2.
Lone A, Salunkhe R, Sugumar V, Zhan L, Ye X, Bezjak A, et al.
Clin Transl Radiat Oncol
. 2025 Feb;
51:100917.
PMID: 39898331
Background: The role of prophylactic cranial irradiation (PCI) is not well-defined in extensive-stage SCLC (ES-SCLC), with conflicting results from randomized trials and a lack of relevant data for patients who...
3.
Palma D, Giuliani M, Correa R, Schneiders F, Harrow S, Guckenberger M, et al.
BMC Palliat Care
. 2024 Sep;
23(1):223.
PMID: 39244532
Background: Emerging randomized data, mostly from phase II trials, have suggested that patients with oligometastatic cancers may benefit from ablative treatments such as stereotactic ablative radiotherapy (SABR). However, phase III...
4.
Giannopoulos E, Moody L, Mackinnon R, Gill B, Giuliani M, Papadakos J
Support Care Cancer
. 2024 Sep;
32(10):631.
PMID: 39227513
Purpose: Positive patient experiences can lead to better adherence to cancer treatment and greater patient health outcomes. The primary aim of this descriptive study was to determine whether commonly used...
5.
Schellenberg D, Gabos Z, Duimering A, Debenham B, Fairchild A, Huang F, et al.
Int J Radiat Oncol Biol Phys
. 2024 Aug;
121(1):28-38.
PMID: 39168356
Purpose: This trial examined if patients with ≤5 sites of oligoprogression benefit from the addition of SABR to standard of care (SOC) systemic therapy. Methods And Materials: We enrolled patients...
6.
Giuliani M, Filion E, Faria S, Kundapur V, Vu T, Lok B, et al.
Int J Radiat Oncol Biol Phys
. 2024 Apr;
120(3):669-677.
PMID: 38614279
Purpose: The use of stereotactic body radiation therapy for tumors in close proximity to the central mediastinal structures has been associated with a high risk of toxicity. This study (NCT03306680)...
7.
Palma D, Bahig H, Hope A, Harrow S, Debenham B, Louie A, et al.
JAMA Oncol
. 2024 Mar;
10(5):575-582.
PMID: 38451491
Importance: Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR),...
8.
Safavi A, Palma D, Giuliani M
Int J Radiat Oncol Biol Phys
. 2023 Nov;
117(5):1232-1235.
PMID: 37980143
No abstract available.
9.
Ugas M, Avery L, Wang Y, Berlin A, Giuliani M, Krzyzanowska M, et al.
Curr Oncol
. 2022 Nov;
29(11):8917-8936.
PMID: 36421354
Background: The novel coronavirus that has triggered the present COVID-19 pandemic continues to spread globally, resulting in widespread morbidity and mortality. Patients with cancer remain one of the most vulnerable...
10.
Huang S, Jacinto J, OSullivan B, Su J, Kim J, Ringash J, et al.
Cancer
. 2022 May;
128(15):2908-2921.
PMID: 35588085
Background: The objective of this study was to describe the clinical presentation and outcomes of human papillomavirus (HPV)-positive nasopharyngeal cancer (NPC) versus Epstein-Barr virus (EBV)-positive NPC and HPV-positive oropharyngeal cancer...